Contribution of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP) to the ongoing debate on the value of prostate cancer screening

Contribution of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP) to the ongoing debate on the value of prostate cancer screening

Bibliográfalaš dieđut
Váldodahkkit:	Martin, RM, Dixon, PC, Turner, E, Keeney, E
Materiálatiipa:	Journal article
Giella:	English
Almmustuhtton:	Wiley 2022

Geahča maid

Validating the use of Hospital Episode Statistics data and comparison of costing methodologies for economic evaluation: an end-of-life case study from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP).
Dahkki: Thorn, J, et al.
Almmustuhtton: (2016)

Validating the use of Hospital Episode Statistics data and comparison of costing methodologies for economic evaluation: an end-of-life case study from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP)
Dahkki: Richard M Martin, et al.
Almmustuhtton: (2016-04-01)

Prostate cancer: estimating the benefits of PSA screening.
Dahkki: Vickers, A, et al.
Almmustuhtton: (2009)

Prostate cancer recurrence in the urethra with low PSA
Dahkki: Shravankrishna Ananthapadmanabhan, et al.
Almmustuhtton: (2024-07-01)

Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality: The CAP randomized clinical trial
Dahkki: Martin, RM, et al.
Almmustuhtton: (2018)

Utility of PSA isoform-[-2] proPSA (p2PSA) and prostate health index in the diagnosis of prostate cancer: A study in Indian population
Dahkki: Govinda Raju NL, et al.
Almmustuhtton: (2022-01-01)

Active surveillance of prostate cancer - an ongoing concept
Dahkki: Daniel Xavier Lima
Almmustuhtton: (2023-01-01)

Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivo.
Dahkki: Denmeade, SR, et al.
Almmustuhtton: (2003)

Association of BMI and Age with Gleason Score and PSA in Patients with Prostate Cancer
Dahkki: SA Mazloumi, et al.
Almmustuhtton: (2023-03-01)

Quantitative PSA RT-PCR for preoperative staging of prostate cancer.
Dahkki: Kurek, R, et al.
Almmustuhtton: (2003)

THE PROGNOSTIC VALUE OF BASELINE PSA BLOOD IN THE TREATMENT OF PROSTATE CANCER
Dahkki: A. A. Gritskevich, et al.
Almmustuhtton: (2017-02-01)

PSA DENSITY - A MARKER FOR POORLY-DIFFERENTIATED PROSTATE CANCER
Dahkki: Tosho Ganev
Almmustuhtton: (2025-02-01)

Commentary: On measurement error, PSA doubling time, and prostate cancer
Dahkki: Lawrence L. Kupper, et al.
Almmustuhtton: (2023-12-01)

Association of reported prostate cancer risk alleles with PSA levels among men without a diagnosis of prostate cancer.
Dahkki: Wiklund, F, et al.
Almmustuhtton: (2009)

The Percentage of Free PSA and Urinary Markers Distinguish Prostate Cancer from Benign Hyperplasia and Contribute to a More Accurate Indication for Prostate Biopsy
Dahkki: Zlata Huskova, et al.
Almmustuhtton: (2020-06-01)

Variation in percentage-free prostate-specific antigen (PSA) with prostate volume, age and total PSA level.
Dahkki: Törnblom, M, et al.
Almmustuhtton: (2001)

Can PSA velocity predict risk of death in men with prostate cancer?
Dahkki: Lilja, H, et al.
Almmustuhtton: (2007)

Commentary on the commentary “On measurement error, PSA doubling time, and prostate cancer”
Dahkki: Lawrence L. Kupper, et al.
Almmustuhtton: (2025-06-01)

PSA and Beyond: The Past, Present, and Future of Investigative Biomarkers for Prostate Cancer
Dahkki: Jeffrey Tosoian, et al.
Almmustuhtton: (2010-01-01)

Ultrasensitive PSA: rethinking post-surgical management for node positive prostate cancer
Dahkki: Jonathan A. Aguiar, et al.
Almmustuhtton: (2024-04-01)

Role of hK2, free PSA, and complexed PSA measurements in the very early detection of prostate cancer.
Dahkki: Lilja, H
Almmustuhtton: (2001)

Clinical application of p2PSA and its derivatives (%p2PSA and Phi) in the diagnosis of prostate cancer
Dahkki: Weiwang Cai, et al.
Almmustuhtton: (2023-11-01)

Blue Cap Relay Run for Prostate Cancer®
Dahkki: Sothilingam, S., et al.
Almmustuhtton: (2016)

Contribution of a single repeat PSA test to prostate cancer risk assessment: experience from the ProtecT study.
Dahkki: Rosario, D, et al.
Almmustuhtton: (2008)

Uji diagnostik prostate spesific antigen (PSA) pada keganasan prostat
Dahkki: , DAHESIHDEWI, Andaru, et al.
Almmustuhtton: (2002)

PROSTATE CANCER WITH A HIGH BASELINE PSA LEVEL AFTER COMBINED TREATMENT
Dahkki: A. T. Asratov, et al.
Almmustuhtton: (2017-12-01)

Finding the PSA-based screening stopping age using prostate cancer risk
Dahkki: Azin Nahvijou, et al.
Almmustuhtton: (2024-01-01)

Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis.
Dahkki: Roddam, A, et al.
Almmustuhtton: (2005)

On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer.
Dahkki: Bangma, C, et al.
Almmustuhtton: (2010)

Allele-specific methylation of the PSA promoter in prostate cells: A new translational marker for the differential diagnosis of prostate cancer
Dahkki: Mikhail Baryshev, et al.
Almmustuhtton: (2025-05-01)

Associations of CYLD, JAK2 and TLR4 Genotypes with PSA Levels and Immunophenotype in Benign Prostatic Hyperplasia and Prostate Cancer
Dahkki: Le Vu Duy, et al.
Almmustuhtton: (2024-07-01)

Screening for prostate cancer: evidence, ongoing trials, policies and knowledge gaps
Dahkki: Anssi Auvinen, et al.
Almmustuhtton: (2023-08-01)

Association between polymorphisms in the prostate-specific antigen (PSA) promoter and release of PSA.
Dahkki: Sävblom, C, et al.
Almmustuhtton: (2009)

Optimal PSA density threshold for prostate biopsy in benign prostatic obstruction patients with elevated PSA levels but negative MRI findings
Dahkki: Yiji Peng, et al.
Almmustuhtton: (2025-03-01)

A PSA SNP associates with cellular function and clinical outcome in men with prostate cancer
Dahkki: Srilakshmi Srinivasan, et al.
Almmustuhtton: (2024-11-01)

PSA testing for prostate cancer: an online survey of the views and reported practice of General Practitioners in the UK
Dahkki: Brett, J, et al.
Almmustuhtton: (2005)

We need a better marker for prostate cancer. How about renaming PSA?
Dahkki: Vickers, A, et al.
Almmustuhtton: (2012)

Survival and PSA relapse data after hypofiractionated radiotherapy for early stage prostate cancer
Dahkki: Law, A, et al.
Almmustuhtton: (2007)

A PSA SNP associates with cellular function and clinical outcome in men with prostate cancer
Dahkki: Srinivasan, S, et al.
Almmustuhtton: (2024)

Associations of adiponectin and leptin with stage and grade of PSA-detected prostate cancer: the ProtecT study.
Dahkki: Burton, A, et al.
Almmustuhtton: (2013)